University of British Columbia Hospital
Welcome,         Profile    Billing    Logout  
 28 Trials 
46 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lam, Stephen
NCT04931017: Metformin for Chemoprevention of Lung Cancer in Overweight or Obese Individuals at High Risk for Lung Cancer

Recruiting
2
50
Canada, US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bronchoscopy, Extended Release Metformin Hydrochloride, ER Metformin Hydrochloride, Extended-release Metformin Hydrochloride, Glucophage XR, Glumetza, Metformin Hydrochloride Extended Release, Questionnaire Administration
National Cancer Institute (NCI)
Lung Carcinoma
04/26
11/26
Young, Allan
INTENSIFY SZ, NCT05958875: The Effect of a Six Week Intensified Pharmacological Treatment for Schizophrenia Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.

Recruiting
4
418
Europe
Clozapine, ATC code: N05AH02, Second-line Antipsychotics (treatment as usual)
Dr. Inge Winter, Universität Münster
Schizophrenia and Related Disorders, Early Treatment-Resistance
06/26
06/26
ELICE_BD, NCT02731612: Study of the Efficacy of Lurasidone in Cognitive Functioning in Bipolar Patients

Recruiting
3
150
Europe, Canada, Japan, US
lurasidone, Latuda, Placebo
Nazlin Walji
Bipolar Disorder
12/24
03/25
INTENSIFY MDD, NCT05973851: The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.

Recruiting
3
418
Europe
Esketamine Nasal Product, ATC code: N06AB10, Ketamine Hydrochloride, N01AX03, Esketamine hydrochloride, N015X14, Second-line Antidepressants
Dr. Inge Winter, Universität Münster
Major Depressive Disorder, Treatment Resistant Depression
06/26
06/26
INTENSIFY BD, NCT05973786: The Effect of a Six Week Intensified Pharmacological Treatment for Bipolar Depression Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.

Recruiting
3
418
Europe
Escitalopram, ATC code: N06AB10, Sertraline, ATC code: N06AB06, Venlafaxine, ATC code: N06AX16, Lithium, ATC code: N05AN01, Valproate acid, ATC code: N03AG01, Quetiapine, ATC code: N05AH04
Dr. Inge Winter, Universität Münster
Bipolar Depression
06/26
06/26
GO-MARK, NCT04977674: Glutamate and Opioid Mechanisms of Antidepressant Response to Ketamine

Completed
1
27
Europe
Naltrexone, Placebo, Ketamine
King's College London
Depressive Disorder, Treatment-Resistant
02/23
02/23
NCT03633357: Imaging 5HT7 Antagonist Effects in Bipolar Disorder

Recruiting
N/A
68
Europe
JNJ-18038683, Placebo
King's College London
Bipolar Disorder
06/22
06/22
RHAPSODY, NCT04939818: Clinical Feasibility of Speech Phenotyping for Remote Assessment of Neurodegenerative and Psychiatric Disorders

Completed
N/A
172
Europe
Novoic Limited, King's College London
Alzheimer Disease, Mild Cognitive Impairment, Dementia With Lewy Bodies, Dementia, Vascular, Frontotemporal Dementia, Primary Progressive Aphasia, Parkinson Disease, Motor Neuron Disease, Major Depressive Disorder, Bipolar Disorder, Amyotrophic Lateral Sclerosis
09/22
09/22
PSY-PGx, NCT05656469: Clinical Study Evaluating Pharmacogenomics-informed Pharmacotherapy Versus Dosing As Usual in Psychiatric Disorders

Recruiting
N/A
2500
Europe, US, RoW
Personalised medication advice based on pharmacogenetic testing
Maastricht University Medical Center, Parnassia Psychiatric Institute, University of Belgrade, University of Bonn, Babes-Bolyai University, State University of New York - Upstate Medical University, Ludwig-Maximilians - University of Munich, King's College London, University of Barcelona
Mood Disorders, Anxiety Disorders, Psychotic Disorders
03/25
03/25
RESTORE-LIFE, NCT03320304: A Study to Assess Effectiveness and Efficiency of VNS Therapy in Patients with Difficult to Treat Depression.

Recruiting
N/A
500
Europe
Vagal Nerve Simulation (VNS) Therapy
LivaNova
Treatment Resistant Depression
12/26
12/28
Macadam, Sheina
Breast_ADM, NCT04661501: BREAST ADM Trial for Alloplastic Breast Reconstruction

Recruiting
N/A
328
Canada
AlloDerm, AlloMax, DermACELL, Flex HD
University of British Columbia
Breast Reconstruction
12/25
12/25
Traboulsee, Anthony
NCT01118130: Pharmacogenomics of Drug Safety in Multiple Sclerosis

Recruiting
N/A
300
Canada
University of British Columbia, Canadian Institutes of Health Research (CIHR), Canada Foundation for Innovation, Genome Canada, British Columbia Clinical Genomics Network
Multiple Sclerosis
05/25
05/25
Savage, Kerry
STOP-GAP, NCT02821013: Duration of Anti-PD-1 Therapy in Metastatic Melanoma

Recruiting
3
614
Canada, RoW
Intermittent PD-1 inhibitor therapy, Continuous PD-1 inhibitor therapy
Canadian Cancer Trials Group, Melanoma and Skin Cancer Trials Limited
Unresectable/Metastatic Melanoma
12/27
12/29
NCT05180097: Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma

Recruiting
2
84
Canada, RoW
Gemcitabine, Dexamethasone, Cisplatin, Brentuximab vedotin, Pembrolizumab
Canadian Cancer Trials Group, Merck Sharp & Dohme LLC, Seagen Inc., Australasian Leukaemia and Lymphoma Group
Hodgkin Lymphoma
06/25
06/26
CA209-447, NCT03033914: A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)

Active, not recruiting
1/2
82
Canada, US
doxorubicin, Bleomycin, vinblastine, dacarbazine, Nivolumab
Memorial Sloan Kettering Cancer Center, Bristol-Myers Squibb, Barbara Ann Karmanos Cancer Institute, British Columbia Cancer Agency
Hodgkin Lymphoma
01/26
01/26
Chin, Patrick
TMGlenoid, NCT01539122: Clinical Experience With the Zimmer Trabecular Metal (TM) Glenoid in Total Shoulder Arthroplasty

Completed
N/A
104
Canada
Zimmer TM Glenoid, Zimmer Trabecular Metal Glenoid, Cemented Glenoid, Cemented all-polyethylene glenoid component (Zimmer)
Joint Preservation Centre of BC
Osteoarthritis of the Shoulder
12/22
12/22
Fisher, Charles
MTRON, NCT02830451: Metastatic Tumor Research and Outcomes Network

Recruiting
N/A
960
Europe, Canada, Japan, US, RoW
AO Innovation Translation Center, AO Foundation, AO Spine
Metastatic Spine Tumor
12/25
12/25
Hsiung, Robin
REFOCUS-ALZ, NCT05026177: Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease

Terminated
3
1125
Canada, US, RoW
Simufilam, PTI-125, Placebo
Cassava Sciences, Inc., Premier Research Group plc
Alzheimer Disease
12/24
12/24
ENVISION, NCT05310071 / 2022-001671-14: A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

Terminated
3
1027
Europe, Canada, Japan, US, RoW
Aducanumab, BIIB037, Aducanumab-avwa, Aduhelm, Placebo
Biogen, Biogen Idec Research Limited
Alzheimer's Disease
08/24
08/24
DIAN-TU-002, NCT06647498: A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

Recruiting
2/3
280
Europe, Canada, US, RoW
Remternetug, LY3372993, Matching Placebo (Remternetug)
Washington University School of Medicine, Alzheimer's Association, Eli Lilly and Company, National Institute on Aging (NIA), GHR Foundation, Private Donors
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
03/34
08/34
DIAN-TU, NCT05269394: Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation

Active, not recruiting
2/3
197
Europe, Canada, Japan, US, RoW
E2814, Lecanemab, BAN2401, Matching Placebo (E2814)
Washington University School of Medicine, Alzheimer's Association, National Institute on Aging (NIA), Accelerating Medicines Partnership (AMP), Eisai Inc.
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
04/28
07/28
DIAN-TU, NCT01760005 / 2013-000307-17: Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol -001

Checkmark From DIAN-TU trial
Feb 2020 - Feb 2020: From DIAN-TU trial
Checkmark Top-line data from DIAN-TU trial in rare inherited form of Alzheimer's disease
Feb 2020 - Feb 2020: Top-line data from DIAN-TU trial in rare inherited form of Alzheimer's disease
Checkmark DIAN TU: N=210
More
Recruiting
2/3
490
Europe, Canada, Japan, US, RoW
Gantenerumab, RO4909832, Solanezumab, LY2062430, Matching Placebo (Gantenerumab), Matching Placebo (Solanezumab), E2814, Lecanemab, BAN2401, Matching Placebo (E2814)
Washington University School of Medicine, Eli Lilly and Company, Hoffmann-La Roche, Alzheimer's Association, National Institute on Aging (NIA), Avid Radiopharmaceuticals, Accelerating Medicines Partnership (AMP), Eisai Inc., Janssen, LP
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
04/28
07/28
DIAN-TU, NCT05552157: A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

Recruiting
2/3
280
Europe, Canada, US, RoW
Remternetug (SC), Matching Placebo (Remternetug)
Washington University School of Medicine, Alzheimer's Association, Eli Lilly and Company, National Institute on Aging (NIA)
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
03/34
08/34
SARTAN-AD, NCT02085265: Telmisartan vs. Perindopril in Mild-Moderate Alzheimer's Disease Patients

Recruiting
2
150
Canada
Perindopril, Coversyl, Telmisartan, Micardis
Sunnybrook Health Sciences Centre, Alzheimer's Drug Discovery Foundation, Weston Brain Institute
Alzheimer's Disease
09/23
09/23
CELIA, NCT05399888: A Study to Learn About the Safety of BIIB080 Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

Active, not recruiting
2
416
Europe, Canada, Japan, US, RoW
BIIB080, ISIS 814907, BIIB080-matching placebo
Biogen
Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia
05/26
01/29
COMPASS-ND, NCT03402919: Comprehensive Assessment of Neurodegeneration and Dementia

Recruiting
N/A
2300
Canada
McGill University, Canadian Institutes of Health Research (CIHR), Alzheimer Society of Canada, Sanofi, New Brunswick Health Research Foundation, Saskatchewan Health Research Foundation, Women's Brain Health Initiative, Michael Smith Foundation for Health Research, Alzheimer's Research UK, Alberta Prion Research Institute, Nova Scotia Health Research Foundation, Eli Lilly and Company, Canadian Nurses Foundation (CNF), Ontario Brain Institute, Consortium pour l'Identification precoce du Maladie Alzheimer du Quebec, Pfizer, Canadian Consortium on Neurodegeneration in Aging
Dementia
09/23
09/23
ADNI3, NCT02854033: Alzheimer's Disease Neuroimaging Initiative 3

Recruiting
N/A
2000
Canada, US
University of Southern California, Northern California Institute of Research and Education, National Institute on Aging (NIA), Alzheimer's Therapeutic Research Institute
Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD)
12/24
12/24
MITNEC C6, NCT02330510: Amyloid and Glucose PET Imaging in Alzheimer and Vascular Cognitive Impairment Patients With Significant White Matter Disease

Completed
N/A
80
Canada
Dr. Sandra E Black
Alzheimer's Disease, Small Vessel Disease White Matter Hyperintensities Subtype, Vascular Cognitive Impairment
12/24
12/24
Rosin, Miriam
NCT05121051: Testing the Effect of the Broccoli Seed and Sprout Extract, Avmacol ES, on the Cancer Causing Substances of Tobacco in Heavy Smokers

Recruiting
2
120
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Broccoli Sprout/Broccoli Seed Extract Supplement, Avmacol, Placebo Administration, Questionnaire Administration
National Cancer Institute (NCI)
Cigarette Smoking-Related Carcinoma
12/25
12/27
NCT05237960: Metformin for the Prevention of Oral Cancer in Patients with Oral Leukoplakia or Erythroplakia

Recruiting
2
86
Canada, US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Extended Release Metformin Hydrochloride, ER Metformin Hydrochloride, Extended-release Metformin Hydrochloride, Glucophage XR, Glumetza, Metformin Hydrochloride Extended Release, Placebo Administration
University of Arizona, National Cancer Institute (NCI)
Erythroplakia, Oral Leukoplakia
08/26
08/28
Wilson, Jason D
NCT05894577: ACTIV-6: COVID-19 Study of Repurposed Medications - Arm F (Montelukast)

Completed
3
1453
US
Placebo, Montelukast
Susanna Naggie, MD, National Center for Advancing Translational Sciences (NCATS), Vanderbilt University Medical Center
Covid19
07/23
01/24
NCT04885530: ACTIV-6: COVID-19 Study of Repurposed Medications

Completed
3
10956
US
Ivermectin, Ivermectin Tablets, Fluvoxamine, Fluvoxamine Maleate Tablets, Fluticasone, Fluticasone Furoate, Placebo, Montelukast, Metformin
Susanna Naggie, MD, National Center for Advancing Translational Sciences (NCATS), Vanderbilt University Medical Center
Covid19
04/24
04/24
NCT06042855: ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)

Completed
3
3214
US
Placebo, Metformin
Susanna Naggie, MD, National Center for Advancing Translational Sciences (NCATS), Vanderbilt University Medical Center
Covid19
06/24
11/24
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( )

Recruiting
3
1000
Europe, Canada, US, RoW
IVA337, Lanifibranor, Placebo
Inventiva Pharma
NASH - Nonalcoholic Steatohepatitis
09/25
09/26
NCT04225598: Emergency Department-Initiated Buprenorphine Validation Network Trial

Completed
2
2000
US
CAM2038, Buprenorphine Sublingual Product
Yale University, National Drug Abuse Treatment Clinical Trials Network, The Emmes Company, LLC, Harvard Medical School (HMS and HSDM), University of Pennsylvania, NYU Langone Health, Icahn School of Medicine at Mount Sinai, Alameda Health System, Weill Medical College of Cornell University, National Institute on Drug Abuse (NIDA)
Opioid-use Disorder
12/24
12/24
CARPO, NCT04681066: A Study of Auxora in Patients With Acute Pancreatitis and Accompanying SIRS

Completed
2
216
US, RoW
CM-4620 Injectable Emulsion or CM-4620-IE, Auxora, Placebo
CalciMedica, Inc.
Acute Pancreatitis, Systemic Inflammatory Response Syndrome
05/24
05/24
NCT03789162: Blood and Stool Sample Collection in Subjects with a Diagnosis of Colorectal Cancer or Colorectal Lesion: Act Fast

Active, not recruiting
N/A
1500
Canada, US
Exact Sciences Corporation
Colorectal Cancer
04/25
04/25
NACTN, NCT00178724: Spinal Cord Injury Registry - North American Clinical Trials Network

Recruiting
N/A
1500
Canada, US
No Treatment Given
Robert G. Grossman, MD, Christopher Reeve Paralysis Foundation, The Methodist Hospital Research Institute, The University of Texas Health Science Center, Houston, University of Virginia, University of Louisville, University of Toronto, University of Maryland, Baltimore, Walter Reed National Military Medical Center, Thomas Jefferson University, University of Miami, Brooke Army Medical Center, Louisiana State University Health Sciences Center in New Orleans, Vanderbilt University Medical Center, Medical College of Wisconsin, Duke University
Spinal Cord Injury
07/25
07/28
NCT05388188: DSUVIA in Patients With SCD VOC Present in the ED

Recruiting
N/A
100
US
sublingual sufentanil, Dsuvia Sublingual Product
Jason Wilson
Sickle-Cell Disease With Crisis
04/23
12/23
Yendamuri, Saikrishna
NCT04067830: Respiratory Muscle Training Before Surgery in Preventing Lung Complications in Patients With Stage I-IIIB Lung Cancer

Recruiting
2
220
US
Best Practice, standard of care, standard therapy, Laparoscopic Surgery, laparoscopic-assisted resection, laparoscopy-assisted surgery, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Respiratory Muscle Training Device, Video-Assisted Thoracic Surgery, VATS
Roswell Park Cancer Institute, National Cancer Institute (NCI)
Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
03/25
03/26
NCT04931017: Metformin for Chemoprevention of Lung Cancer in Overweight or Obese Individuals at High Risk for Lung Cancer

Recruiting
2
50
Canada, US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bronchoscopy, Extended Release Metformin Hydrochloride, ER Metformin Hydrochloride, Extended-release Metformin Hydrochloride, Glucophage XR, Glumetza, Metformin Hydrochloride Extended Release, Questionnaire Administration
National Cancer Institute (NCI)
Lung Carcinoma
04/26
11/26
NCT04836429: Photodynamic Therapy to Amplify the Response to Immunotherapy in Patients With Non-small Cell Lung Cancer With Pleural Disease

Active, not recruiting
1
5
US
Porfimer Sodium, 87806-31-3, CL-184116, Dihematoporphyrin Ester, Photofrin II, Video-Assisted Thoracic Surgery, VATS, Photodynamic Therapy, PDT, Intraoperative PDT, intra-operative photo dynamic therapy
Roswell Park Cancer Institute
Lung Non-Small Cell Carcinoma, Pleural Disorder
02/24
01/26
NCT03678350: Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery

Active, not recruiting
1
9
US
Light Dosimetry for Intranoperative Therapy, Photodynamic Therapy, PDT, Photoradiation Therapy, Porfimer Sodium, CL-184116, DHE, Dihematoporphyrin Ester, dihematoporphyrin ether, Photofrin II
Roswell Park Cancer Institute, Lumeda,Inc.
Malignant Mesothelioma, Non-Small Cell Lung Carcinoma, Pleural Disorder
11/23
10/25
Brubacher, Jeff
NCT05581810: Rehabilitation for Functional Memory Symptoms After Concussion

Completed
N/A
30
Canada
Cognitive Behavioural Therapy (CBT), Cognitive Rehabilitation
University of British Columbia, Harvard Medical School (HMS and HSDM)
Mild Traumatic Brain Injury, Functional Neurological Disorder
06/23
11/23
Moe, Jessica
NCT04893525: Evaluating Buprenorphine/Naloxone Microdosing vs. Standard Dosing in Emergency Departments

Recruiting
2/3
658
Canada
Buprenorphine/naloxone, Suboxone
University of British Columbia
Opioid-use Disorder
12/24
06/25
McPherson, Anabelle
MAST, NCT06672588: Magnetic Seizure Therapy for Schizophrenia - Trial

Not yet recruiting
N/A
80
Canada
Magnetic Seizure Therapy (MST), MST, Electroconvulsive Therapy (ECT), ECT
Centre for Addiction and Mental Health, University of British Columbia
Treatment Resistant Schizophrenia, Schizophrenia, Schizoaffective Disorder
11/28
11/28

Download Options